Safety First For Perrigo In CBD Market; ‘Long-Term’ Play Starts With Clinical Trials
Executive Summary
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.
You may also be interested in...
Reaching 'Transformation' In Turnaround Phase 1, Perrigo Looks To Build On Its Accomplishments
Day after releasing Q4 and full-year results, Perrigo announced launch of next chapter in its “3/5/7” makeover strategy. It reached annual growth of 3% for top line revenues in phase 1, aims for 5% operating income and 7% earnings per share growth in phase 2.
Thinking About Entering The EU CBD Market? Some Food For Thought
Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal.
With ‘CBD HQ,' Vitamin Shoppe Reflects US Industry Confidence In Cannabidiols Market's Future
Vitamin Shoppe rolls out CBD HQ sections in 572 stores in 39 states, citing strong word-of-mouth demand for products. The national retailer’s move could reflect growing bullishness by industry after FDA sent unpublished draft guidance on CBD enforcement for White House clearance.